Kornitzer Capital Management Inc. KS trimmed its holdings in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) by 47.6% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 511,931 shares of the company's stock after selling 464,570 shares during the quarter. Kornitzer Capital Management Inc. KS owned about 0.60% of Progyny worth $8,831,000 at the end of the most recent quarter.
Other hedge funds have also recently bought and sold shares of the company. GAMMA Investing LLC boosted its holdings in Progyny by 341.4% during the fourth quarter. GAMMA Investing LLC now owns 1,611 shares of the company's stock valued at $28,000 after acquiring an additional 1,246 shares during the period. Nisa Investment Advisors LLC boosted its holdings in Progyny by 108.4% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,934 shares of the company's stock valued at $51,000 after acquiring an additional 1,526 shares during the period. Caitlin John LLC boosted its holdings in Progyny by 2,974.8% during the fourth quarter. Caitlin John LLC now owns 3,290 shares of the company's stock valued at $57,000 after acquiring an additional 3,183 shares during the period. Meeder Asset Management Inc. bought a new stake in Progyny during the third quarter valued at about $77,000. Finally, KBC Group NV boosted its holdings in Progyny by 84.6% during the fourth quarter. KBC Group NV now owns 4,669 shares of the company's stock valued at $81,000 after acquiring an additional 2,140 shares during the period. 94.93% of the stock is owned by institutional investors and hedge funds.
Analyst Ratings Changes
Several equities research analysts recently weighed in on PGNY shares. Canaccord Genuity Group reduced their target price on shares of Progyny from $18.00 to $17.00 and set a "hold" rating for the company in a research note on Wednesday, November 13th. Truist Financial reiterated a "hold" rating and issued a $19.00 target price (down previously from $26.00) on shares of Progyny in a research note on Wednesday, November 13th. Barclays reduced their target price on shares of Progyny from $30.00 to $17.00 and set an "overweight" rating for the company in a research note on Thursday, November 14th. Bank of America increased their target price on shares of Progyny from $21.00 to $25.00 and gave the company a "buy" rating in a research note on Tuesday, February 11th. Finally, JPMorgan Chase & Co. increased their target price on shares of Progyny from $17.00 to $23.00 and gave the company a "neutral" rating in a research note on Tuesday, January 28th. Nine investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, Progyny presently has an average rating of "Hold" and a consensus price target of $25.83.
Read Our Latest Stock Analysis on PGNY
Progyny Stock Performance
Shares of NASDAQ PGNY traded down $0.68 during mid-day trading on Friday, hitting $23.20. 1,243,035 shares of the stock were exchanged, compared to its average volume of 1,799,572. The company has a market cap of $1.98 billion, a P/E ratio of 40.00, a PEG ratio of 2.37 and a beta of 1.34. The stock's fifty day simple moving average is $19.67 and its two-hundred day simple moving average is $18.68. Progyny, Inc. has a twelve month low of $13.39 and a twelve month high of $40.89.
Insider Transactions at Progyny
In other news, CEO Peter Anevski acquired 209,500 shares of the company's stock in a transaction dated Monday, December 23rd. The stock was bought at an average price of $14.48 per share, with a total value of $3,033,560.00. Following the completion of the acquisition, the chief executive officer now owns 441,463 shares in the company, valued at approximately $6,392,384.24. This represents a 90.32 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Chairman David J. Schlanger acquired 150,000 shares of the company's stock in a transaction dated Thursday, December 26th. The shares were purchased at an average cost of $14.68 per share, with a total value of $2,202,000.00. Following the acquisition, the chairman now owns 228,269 shares of the company's stock, valued at approximately $3,350,988.92. This represents a 191.65 % increase in their position. The disclosure for this purchase can be found here. Company insiders own 12.30% of the company's stock.
Progyny Company Profile
(
Free Report)
Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.
Read More
Before you consider Progyny, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Progyny wasn't on the list.
While Progyny currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
